Parameters | Overall response at day 10 after treatment | Overall survival | Failure-free survival | |||
---|---|---|---|---|---|---|
 | Univariable OR (95%CI) P value | Multivariable OR (95%CI) P value | Univariable HR (95%CI) P value | Multivariable HR (95%CI) P value | Univariable HR (95%CI) P value | Multivariable HR (95%CI) P value |
Gender female vs male | 1.92(0.70–5.24); .20 | - | 1.30(0.36–4.62); .67 | - | 0.74(0.46–1.21); .23 | - |
Patient age  < 35 vs ≥ 35 years (median) | 1.05(0.39–2.82); .90 | - | 0.40(0.10–1.55); .18 | - | 1.18(0.72–1.92); .49 | - |
MAGIC criteria grade I-II vs III-IV | 17.18(4.67–63.16); * < .001 | 20.12(4.28–94.37); * < .001 | 0.18(0.04–0.73); *.016 | 0.18(0.04–0.73); *.016 | 0.22(0.11–0.45); * < .001 | 0.26(0.13–0.52); * < .001 |
GVHD risk category standard vs high | 29.06(6.57–128.35); * < .001 | - | 0.15(0.03–0.58); *.006 | - | 0.19(0.09–0.40); * < .001 | - |
Underlying malignancy AML/MDS vs ALL or others | 0.79(0.281–2.24); .66 | - | 2.46(0.52–11.61); .25 | - | 1.20(0.72–2.00); .47 | - |
Graft source PB vs BM | 0.96(0.25–3.60); .96 | - | 1.85(0.23–14.60); .55 | - | 0.71(0.39–1.29); .26 | - |
Donor source | .71 | - | .43 | - | .33 | - |
Matched sibling | 0.56(0.14–2.20); .41 |  | 0.00 .98 |  | 1.45(0.74–2.83); .27 |  |
Unrelated donor | 0.00 .99 |  | 2.72(0.59–12.72); .20 |  | 1.56(0.71–3.41); .26 |  |
Haplo donor | 1.0 | Â | 1.0 | Â | 1.0 | Â |
Center Peking university vs others | 1.47(0.48–4.46); .49 | - | 2.61(0.33–20.66); .36 | - | 0.92(0.52–1.64); .79 | - |
Mini-dose MTX treatment MTX vs control | 8.90(1.96–40.41); *.005 | 9.39(1.81–48.59); *.008 | 0.78(0.21–2.91); .71 | - | 0.46(0.27–0.76); * .002 | 0.49(0.30–0.82); *.007 |